Bio-Sourcing and Tiny Cargo Partner on Orally Delivered mAbs Using Goat Milk Exosomes

Why It Matters

Oral delivery of mAbs would dramatically cut administration costs and boost patient adherence, unlocking a new market for biologics. The collaboration also demonstrates a sustainable, scalable manufacturing model that could lower prices and expand global access.

Key Takeaways

• Goat milk yields high‑volume, low‑cost monoclonal antibodies.
• Tiny Cargo extracts and loads milk exosomes at cGMP scale.
• Oral mAb delivery could eliminate injections and hospital visits.
• Projects target oral Humira and Herceptin formulations.
• Partnership bridges European biotech with U.S. manufacturing.

Pulse Analysis

The promise of oral biologics has long been hampered by the harsh environment of the gastrointestinal tract, which degrades proteins before they reach systemic circulation. Milk‑derived exosomes offer a natural, lipid‑bilayer shield that can protect monoclonal antibodies from enzymatic breakdown and facilitate transport across intestinal epithelium. By leveraging this carrier, companies can pursue stable, shelf‑ready formulations that bypass needles, reduce cold‑chain dependence, and simplify dosing schedules for chronic patients.

Bio‑Sourcing’s BioMilk platform combines CRISPR‑Cas9 gene editing with advanced IVF techniques to generate transgenic goats that secrete therapeutic antibodies directly into milk. This biologic‑in‑milk approach yields gram‑scale antibody quantities at a fraction of traditional bioreactor costs, while simultaneously producing a rich source of extracellular vesicles. The dual output creates an integrated supply chain where the therapeutic and its delivery vehicle originate from the same biological system, enhancing batch consistency and sustainability.

The Tiny Cargo Company complements this model with a cGMP‑ready, industrial‑scale exosome isolation and loading technology originally designed for cow milk but readily adaptable to goat milk. Their platform can incorporate diverse payloads—including mAbs, mRNA, and oligonucleotides—into purified exosomes, meeting stringent pharmaceutical standards. As the collaboration advances oral formulations of adalimumab and trastuzumab, it positions both firms at the forefront of a potential paradigm shift: turning injectable biologics into patient‑friendly oral pills, accelerating market adoption, and reshaping global biologics distribution.